| Product NDC: | 0074-3826 | 
| Proprietary Name: | Depakote | 
| Non Proprietary Name: | Divalproex Sodium | 
| Active Ingredient(s): | 250 mg/1 & nbsp; Divalproex Sodium | 
| Administration Route(s): | ORAL | 
| Dosage Form(s): | TABLET, EXTENDED RELEASE | 
| Coding System: | National Drug Codes(NDC) | 
| Product NDC: | 0074-3826 | 
| Labeler Name: | AbbVie Inc. | 
| Product Type: | HUMAN PRESCRIPTION DRUG | 
| FDA Application Number: | NDA021168 | 
| Marketing Category: | NDA | 
| Start Marketing Date: | 20000804 | 
| Package NDC: | 0074-3826-72 | 
| Package Description: | 5 BLISTER PACK in 1 CARTON (0074-3826-72) > 4 TABLET, EXTENDED RELEASE in 1 BLISTER PACK | 
| NDC Code | 0074-3826-72 | 
| Proprietary Name | Depakote | 
| Package Description | 5 BLISTER PACK in 1 CARTON (0074-3826-72) > 4 TABLET, EXTENDED RELEASE in 1 BLISTER PACK | 
| Product NDC | 0074-3826 | 
| Product Type Name | HUMAN PRESCRIPTION DRUG | 
| Non Proprietary Name | Divalproex Sodium | 
| Dosage Form Name | TABLET, EXTENDED RELEASE | 
| Route Name | ORAL | 
| Start Marketing Date | 20000804 | 
| Marketing Category Name | NDA | 
| Labeler Name | AbbVie Inc. | 
| Substance Name | DIVALPROEX SODIUM | 
| Strength Number | 250 | 
| Strength Unit | mg/1 | 
| Pharmaceutical Classes | Anti-epileptic Agent [EPC],Decreased Central Nervous System Disorganized Electrical Activity [PE],Mood Stabilizer [EPC] |